Predictive Value of IL28B Gene Polymorphism Combined with Pretreatment Serum IP-10 Quantification for Response to Peginterferon and Ribavirin Is Enhanced in Comparison with any of these Biomarkers alone
Number of patents in Portfolio can not be more than 2000
United States of America Patent
Stats
-
N/A
Issued Date -
Oct 4, 2012
app pub date -
Dec 21, 2010
filing date -
Dec 22, 2009
priority date (Note) -
Abandoned
status (Latency Note)
Importance
Loading Importance Indicators... 
Abstract
The current invention relates to a method of combining IL28B genotype determination with pre-treatment serum level measurement of IP-10 to predict the outcome of a sustained virological response (SVR) or non-response to peginterferon and ribavirin for individual patients infected with HCV.
Loading the Abstract Image...
OK
First Claim
Family
Loading Family data...
International Classification(s)
Cited Art Landscape
Patent Citation Ranking
Recipient Email Address
Recipient Email Address
Comment
Recipient Email Address
Add to Portfolio(s)
To add this patent to one, or more, of your portfolios, simply click the add button.
This Patent is in these Portfolios:
Add to additional portfolios:
Last Refreshed On:
Changes done successfully